(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Ciencias Cardiovasculares > Trombosis y hemostasia > DA - CIMA - Cardiovasculares - Trombosis y Hemostasia - Artículos de Revista >

Blocking endothelial protein C receptor (EPCR) accelerates thrombus development in vivo
Autor(es) : Centelles, M.N. (Miguel N.)
Puy, C. (Cristina)
Lopez-Sagaseta, J. (Jacinto)
Fukudome, K. (Kenji)
Montes, R. (Ramón)
Hermida, J. (José)
Palabras clave : Endothelial cell protein C receptor
Protein C
Thrombosi
Monoclonal antibodies
Animal thrombosis models
Fecha incorporación: 2010
Editorial : Schattauer
Versión del editor: http://bit.ly/IKxT1D
ISSN: 0340-6245
Cita: Centelles MN, Puy C, Lopez-Sagaseta J, Fukudome K, Montes R, Hermida J. Blocking endothelial protein C receptor (EPCR) accelerates thrombus development in vivo. Thromb Haemost 2010 Jun;103(6):1239-1244.
Resumen
The endothelial protein C receptor (EPCR) plays an anticoagulant role by improving protein C activation. Although low levels of activated protein C (APC) constitute a thrombosis risk factor, the relationship between modulating EPCR function and thrombosis has not been addressed so far. Monoclonal antibodies (mAb) against murine EPCR were raised, and their ability to block protein C/APC binding was tested. The ferric chloride carotid artery injury model in mice was chosen to test the effect of anti-EPCR mAb on thrombus formation. The time to total occlusion of the vessel was analysed in three groups, given an isotype control mAb (IC), a blocking (RCR-16) or a non-blocking (RCR-20) anti-EPCR mAb. RCR-16 prevented the interaction between protein C/APC and EPCR as demonstrated by surface plasmon resonance and flow cytometry, and inhibited the activation of protein C on the endothelium. IC and RCR-20 were unable to induce such effects. In vivo , RCR-16 shortened the time to total vessel occlusion with respect to IC [13.4 +/- 1.0 (mean +/- SD) and 17.8 +/- 3.2 minutes, respectively, p<0.001]. Occlusive thrombi lasting for more than one hour were observed in all RCR-16-treated animals, but only in 43% of IC-treated ones. Results with RCR-20 were indistinguishable from those observed with IC. For the first time, a direct relationship between blocking EPCR and thrombosis is demonstrated. Blocking anti-EPCR autoantibodies can predispose to thrombosis episodes and may constitute a new therapeutic target.
Enlace permanente: http://hdl.handle.net/10171/21980
Aparece en las colecciones: DA - CIMA - Cardiovasculares - Trombosis y Hemostasia - Artículos de Revista

Ficheros en este registro:
Fichero:  ThrombHaemost2010_1031239.pdf
Descripción: 
Tamaño:  188,7 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.